IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A compound of formula (I) with an optional label:

cyclo [NX_1-R_1-CO-NX_2-R_2-CO-NX_3-R_3-CO-NX_4-R_4-CO-NX_5-R_5-CO]

where: R_1 is selected from the group consisting of :

$CH(CH_2)_3NHC(NH)NH_2$; and $C[CH_nF_m](CH_2)_3NHC(NH)NH_2$;

R_2 is selected from the group consisting of CH_2; and CH_2-CH_2;



;

R_3 is selected from the group consisting of $CHCH_2COOH$; and $C[CH_nF_m]CH_2$-COOH;

R_4 is selected from the group consisting of CH-CH_2-Ph; $C[CH_nF_m]CH_2$-Ph; CH-CH_2-(4-OH)Ph; CH-CH_2-(4-OMe)Ph; CH-CH_2-(4-F)Ph; CH-CH(OH)-Ph; $C(CH_3)_2$; CH-$C(CH_3)$~~$(CH3)_3$~~; and CH-CH_2-COOH;



;

R_5 is selected from the group consisting of CH-CH_2-Ph; $C[CH_nF_m]CH_2$-Ph; CH-$CH(CH_3)_2$; $C[CH_nF_m]CH(CH_3)_2$; and CH-$C(CH_3)_3$;

or, the group NX_4-R_4-CO-NX_5-R_5-CO is 3-aminomethyl-benzoyl;

~~N + M~~n + m = 3;

X_1-X_5, which may be the same or different, are H, or ~~$(CH_2)_n$~~$(CH_2)_e$-CH_3;

-NX$_4$-R$_4$- =  ; 

~~$(CH_2)_n$~~$(CH_2)_p$-CHF_2; ~~$(CH_2)_n$~~$(CH_2)_p$-CH_2F, ~~$(CH_2)_n$~~$(CH_2)_p$-CF_3 where np = 0-3; with the proviso that there is at least one α-fluoroalkylated amino acid present in the formula (I) compound;

where each NX-R-CO amino acid can have an absolute type R or type S configuration; their individual enantiomers, diastereoisomers, the related mixtures, or the pharmaceutically acceptable salts.

2. (currently amended) The compound ~~Compound~~ according to claim 1, selected from the group consisting of:

c (Arg-Gly-Asp-D-Phe-(*R or S*)-Tfm-Phe);

c (Arg-Gly-Asp-D-Phe-(*R, S*)-Dfm-Phe);

~~c (Arg-Gly-Asp-(*R or S*)-Tfm-Phe-Asp-D-Phe-Val);~~

c (Arg-Gly-Asp-(*R or S*)-Tfm-Phe-Val) (SEQ ID NO:1);

c (Arg-Gly-Asp-D-Phe-(*R or S*)-Tfm-Val) and

c (Arg-Gly-Asp-D-Phe-(*R* or *S*)-N-Me-Tfm-Phe.

3. (currently amended) A method of inhibiting receptors belonging to the family of the integrins belonging to the $\alpha_v\beta_3$ and $\alpha_v\beta_5$ system in a human, said method comprising administering a compound according to claim 1 to said human ~~mammal~~ in a manner whereby said receptors are inhibited.

4. (previously presented) A method of preparing a medicament comprising admixing a compound of claim 1 with a pharmaceutically acceptable vehicle or excipient.

5. (previously presented) The method of claim 3 wherein angiogenic activity of said human is inhibited.

6. (previously presented) The method of claim 3 wherein metastatic activity of said human is inhibited.

7. (previously presented) The method of claim 3 wherein said human has disease selected from the group consisting of retinopathy, acute kidney failure, and osteoporosis.

8. (previously Presented) Pharmaceutical compositions containing at least one compound according to claim 1 as an active ingredient in a mixture with pharmaceutically acceptable vehicles and/or excipients.

Claim 9 (canceled)

10. (previously presented) A compound of claim 1 further comprising a label.

11. (previously presented) A method of detecting the location of a tumor in a human comprising administering to said human a compound of claim 10 and detecting said label in said human in a manner whereby the location of said tumor is detected.

12. (previously presented) The method of claim 11 wherein said tumor is a small tumor mass.

13. (previously presented) A method of detecting the location of an arterial occlusion in a human comprising administering to said human a compound of claim 10 and detecting said label in said human in a manner whereby the location of said arterial occlusion is detected.

14. (previously presented) The method of claim 13 wherein said arterial occlusion is the result of a stroke or myocardial infarct.

Claim 15 (canceled)